Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transimmunization for cutaneous T cell lymphoma: a Phase I study.

Michael Girardi1, Carole L Berger, Lynn D Wilson

  • 1Department of Dermatology, Yale University School of Medicine, CT 06520-8059, USA. girardi@yale.edu

Leukemia & Lymphoma
|September 13, 2006
PubMed
Summary

Transimmunization, a revised extracorporeal photochemotherapy (ECP), shows promise for cutaneous T cell lymphoma (CTCL). This novel immunotherapy demonstrated significant reduction in malignant cells and skin lesions with minimal toxicity in a Phase I study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ex vivo Sézary syndrome patient tumor cells are sensitive to ATR inhibition.

The Journal of investigative dermatology·2026
Same author

How We Evaluate and Treat Leukemic Presentations of Mature T-Cell Lymphomas.

Cancers·2026
Same author

Weekly dosing schedule of brentuximab vedotin is well tolerated in mycosis fungoides/Sézary syndrome.

British journal of haematology·2025
Same author

Sclerotic GVHD and scleroderma share dysregulated gene expression that is ameliorated by EREG therapeutic antibody.

Blood·2025
Same author

Syringotropic mycosis fungoides with clinical and histologic features of necrobiosis lipoidica diabeticorum.

JAAD case reports·2025
Same author

ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome.

Journal of the American Academy of Dermatology·2025

Area of Science:

  • Immunotherapy
  • Dermatology
  • Oncology

Background:

  • Extracorporeal photochemotherapy (ECP) is a standard immunotherapy for cutaneous T cell lymphoma (CTCL).
  • ECP involves sequential steps including dendritic cell (DC) generation and presumed in vivo tumor cell loading.
  • A revised procedure, Transimmunization, aims to enhance ex vivo DC-tumor cell interaction.

Purpose of the Study:

  • To assess the safety and efficacy of Transimmunization in CTCL patients.
  • To evaluate a novel methodology for increasing ex vivo contact between apoptotic malignant cells and newly generated DCs.

Main Methods:

  • A single-center, open-label Phase I clinical study.
  • Twenty-seven CTCL patients were treated monthly for 3-5 months with Transimmunization, alone or with electron beam therapy.

Related Experiment Videos

  • Safety and clinical outcomes, including lesion reduction and circulating malignant cell counts, were assessed.

    • Main Results:

    • Transimmunization alone resulted in diminished infiltrative lesions in 55% of patients.
    • In leukemic CTCL patients, a significant mean reduction of 50.1% in circulating malignant cells was observed (P
    • The procedure demonstrated minimal toxicity.

    Conclusions:

    • Transimmunization allows synchronous induction and tumor loading of DCs.
    • This revised ECP approach may be a safe and effective treatment for CTCL.
    • Transimmunization warrants further investigation for CTCL and other malignancies.